Their study demonstrated that localized castration-sensitive BRCA2-mutant tumours are uniquely aggressive due to de novo aberration in genes usually associated with metastatic CRPC disease, justifying aggressive initial treatment. This evidence concerns the gene BRCA2 and neoplasm.